引起的高血压和认知功能障碍:大脑粉样蛋白病理学
Yunbo Zhang1, Yao Xu2, Yanling Song1
1Department of General Practice, The First Affiliated Hospital of Hainan Medical University, No.33, Longhua Road, Haikou, 570102, Hainan, China.
European journal of medical research
|August 7, 2025
概括
暴露会使阿尔茨海默病 (AD) 的病理状况恶化,通过通过矿物质皮质醇受体 (MR) 激活来增加血压和炎症. 在AD小鼠模型中,MR抗剂斯皮罗诺拉克显示出比阿姆洛迪平更大的神经保护作用.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- (Pb) 暴露与认知衰退和阿尔茨海默氏症 (AD) 病理学有关,可能通过高血压.
- 矿物质皮质类受体 (MR) 信号在Pb诱导的AD恶化中的作用尚未完全理解.
研究的目的:
- 调查Pb诱导的高血压是否通过MR激活加剧了粉样蛋白病理.
- 在AD小鼠模型中评估安洛迪平和螺旋作为潜在的治疗药物.
主要方法:
- APPSwDI转基因小鼠被暴露在酸中8周.
- 小鼠同时接受了阿姆洛迪平或螺旋.
- 评估了认知功能,血压,神经炎症,氧化应激和大脑粉样蛋白沉积.
主要成果:
- 暴露增加了血压,认知功能受损,炎症标志物 (IL-1β,IL-6) 升高,大脑粉样蛋白负担增加.
- 脑组织中的MR表达在Pb暴露后得到了上调.
- 两种药物都改善了认知和减少了神经炎症; 螺旋龙在抑制MR表达和粉样沉积方面更有效.
结论:
- 暴露会通过与MR相关的高血压和炎症途径加剧AD类病理.
- 在这个模型中,MR与螺旋龙的对抗作用提供了显著的神经保护.
- 针对MR信号提供了一个潜在的治疗策略,用于环境诱导的AD风险.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K


